Ishida, Junichi

[["dc.bibliographiccitation.firstpage","497"],["dc.bibliographiccitation.journal","Wiener klinische Wochenschrift"],["dc.bibliographiccitation.lastpage","504"],["dc.bibliographiccitation.volume","128"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","dos Santos, Marcelo Rodrigues"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Emami, Amir"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2018-11-07T10:05:07Z"],["dc.date.available","2018-11-07T10:05:07Z"],["dc.date.issued","2016"],["dc.description.abstract","Inadequate nutritional status has been linked to poor outcomes in patients with heart failure (HF). Skeletal muscle wasting affects about 20% of ambulatory patients with HF. The impact of nutritional intake and appetite on skeletal muscle wasting has not been investigated so far. We sought to investigate the impact of nutritional status on muscle wasting and mortality in ambulatory patients with HF. We studied 130 ambulatory patients with HF who were recruited as a part of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) program. Muscle wasting was defined according to criteria of sarcopenia, i.e., appendicular skeletal muscle mass two standard deviations below the mean of a healthy reference group aged 18-40 years. Nutritional status was evaluated using the Mini-Nutritional Assessment-Short Form (MNA-SF). Functional capacity was assessed as peak oxygen consumption (peak VO2) by cardiopulmonary exercise testing, 6aEurominute walk testing, and the Short Physical Performance Battery (SPPB). At baseline, 19 patients (15%) presented with muscle wasting. Patients with muscle wasting had significantly lower values of peak VO2, 6aEurominute walk distance, SPPB, and MNA-SF score than patients without (all p < 0.05). In multivariate analysis, MNA-SF remained an independent predictor of muscle wasting after adjustment for age and New York Heart Association class (odds ratio [OR] 0.66; confidence interval [CI] 0.50-0.88; p < 0.01). A total of 16 (12%) patients died during a mean follow-up of 21 months. In Cox regression analysis, MNA-SF (OR 0.80, CI 0.64-0.99, p = 0.04), left ventricular ejection fraction (OR 0.93, CI 0.86-0.99, p = 0.05), and peak VO2 (OR 0.78, CI 0.65-0.94, p = 0.008) were predictors of death. MNA-SF is an independent predictor of muscle wasting and mortality in ambulatory patients with HF. Nutritional screening should be included as a fundamental part of the overall assessment of these patients."],["dc.identifier.doi","10.1007/s00508-016-1112-8"],["dc.identifier.isi","000390034100011"],["dc.identifier.pmid","27853883"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38838"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","1613-7671"],["dc.relation.issn","0043-5325"],["dc.title","Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","37"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","42"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:22:26Z"],["dc.date.available","2018-11-07T10:22:26Z"],["dc.date.issued","2017"],["dc.description.abstract","Background: Myostatin, a negative regulator of skeletal muscle mass, is up-regulated in the myocardiumof heart failure (HF) and increasedmyostatin is associatedwithweight loss in animal models with HF. Although there are disparities in pathophysiology and epidemiology between male and female patients with HF, it remains unclear whether there is gender difference in myostatin expression and whether it is associated with weight loss in HF patients. Methods: Heart tissue sampleswere collected frompatientswith advanced heart failure (n= 31, female n= 5) as well as healthy control donors (n= 14, female n= 6). Expression levels of myostatin and its related proteins in the heart were evaluated by western blotting analysis. Results: Body mass index was significantly lower in female HF patients than inmale counterparts (20.0 +/- 4.2 in female vs 25.2 +/- 3.8 in male, p= 0.04). In female HF patients, both mature myostatin and pSmad2 were significantly up-regulated by 1.9 fold (p= 0.05) and 2.5 fold (p < 0.01) respectively compared to female donors, while expression of pSmad2was increased by 2.8 times inmale HF patients compared to male healthy subjects, but that of myostatinwas not. Therewas no significant difference in protein expression related tomyostatin signaling between male and female patients. Conclusion: In this study, myostatin and pSmad2 were significantly up-regulated in the failing heart of female patients, but notmale patients, and female patients displayed lower body mass index. Enhancedmyostatin signaling in female failing heart may causally contribute to pathogenesis of HF and cardiac cachexia. (C) 2017 Elsevier B. V. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2017.03.153"],["dc.identifier.isi","000402478900007"],["dc.identifier.pmid","28465115"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42273"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Myostatin signaling is up-regulated in female patients with advanced heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","392"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Saito, Masakazu"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:48:30Z"],["dc.date.available","2018-11-07T09:48:30Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1002/jcsm.12080"],["dc.identifier.isi","000365536800017"],["dc.identifier.pmid","26674220"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35320"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","240"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of the American Medical Directors Association"],["dc.bibliographiccitation.lastpage","245"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Dos Santos, Marcelo Rodrigues"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Emami, Amir"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2018-11-07T10:26:22Z"],["dc.date.available","2018-11-07T10:26:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Objectives: Skeletal muscle wasting, also known as sarcopenia, has recently been identified as a serious comorbidity in patients with heart failure (HF). We aimed to assess the impact of sarcopenia on endothelial dysfunction in patients with HF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). Design: Cross-sectional study. Setting: Ambulatory patients with HF were recruited at Charite Medical School, Campus Virchow-Klinikum, Berlin, Germany. Participants: We assessed peripheral blood flow (arm and leg) in 228 patients with HF and 32 controls who participated in the Studies Investigating Comorbidities Aggravating HF (SICA-HF). Measurements: The appendicular skeletal muscle mass of the arms and the legs combined was assessed by dual energy x-ray absorptiometry (DEXA). Sarcopenia was defined as the appendicular muscle mass two standard deviations below the mean of a healthy reference group of adults aged 18 to 40 years, as suggested for the diagnosis of muscle wasting in healthy aging. All patients underwent a 6-minute walk test and spiroergometry testing. Forearm and leg blood flow were measured by venous occlusion plethysmography. Peak blood flow was assessed after a period of ischemia in the limbs to test endothelial function. Results: Sarcopenia was identified in 37 patients (19.5%). Patients with sarcopenia presented with lower baseline forearm blood flow (2.30 +/- 1.21 vs. 3.06 +/- 1.49 vs. 4.00 +/- 1.66 mL min(-1) 100 mL(-1); P = .02) than those without sarcopenia or controls. The group of patients with sarcopenia showed similar baseline leg blood flow (2.06 +/- 1.62 vs. 2.39 +/- 1.39 mL min(-1) 100 mL(-1); P = .11) to those without but lower values when compared to controls (2.06 +/- 1.62 vs. 2.99 +/- 1.28 mL min(-1) 100 mL(-1); P = .03). In addition, patients with and without sarcopenia presented with lower peak flow in the forearm when compared to controls (18.37 +/- 7.07 vs. 22.19 +/- 8.64 vs. 33.63 +/- 8.57 mL min(-1) 100 mL(-1); P < .001). A similar result was observed in the leg (10.89 +/- 5.61 vs. 14.66 +/- 7.19 vs. 21.37 +/- 13.16 mL min(-1) 100 mL(-1); P < .001). Peak flow in the forearm showed a significant correlation with exercise capacity (relative peak VO2: R = 0.47; P < .001; absolute peak VO2: R = 0.35; P < .001; and 6-min walk distance: R = 0.20; P < .01). Similar correlations were observed between peak flow in the leg and exercise capacity (absolute peak VO2: R = 0.42, P < .001; relative peak VO2: R = 0.41, P < .001; and 6-min walk test: R = 0.33; P < .001). Logistic regression showed peak flow in the leg to be independently associated with the 6-min walk distance adjusted for age, hemoglobin level, albumin, creatinine, presence of sarcopenia, and coronary artery disease (hazard ratio, 0.903; 95% confidence interval, 0.835-0.976; P = .01). Conclusion: Patients with HF associated with sarcopenia have impaired endothelial function. Lower vasodilatation had a negative impact on exercise capacity, particularly prevalent in patients with sarcopenia. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine."],["dc.identifier.doi","10.1016/j.jamda.2016.09.006"],["dc.identifier.isi","000398943400010"],["dc.identifier.pmid","27816483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43027"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1538-9375"],["dc.relation.issn","1525-8610"],["dc.title","Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","852"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","853"],["dc.bibliographiccitation.volume","223"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:05:47Z"],["dc.date.available","2018-11-07T10:05:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1016/j.ijcard.2016.08.289"],["dc.identifier.isi","000387036200224"],["dc.identifier.pmid","27580220"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38966"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Significance of animal models of cardiac cachexia and impact of gender on cardiac cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","62"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","64"],["dc.bibliographiccitation.volume","225"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Baumgarten, Anna"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:04:29Z"],["dc.date.available","2018-11-07T10:04:29Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1016/j.ijcard.2016.09.128"],["dc.identifier.isi","000390472000015"],["dc.identifier.pmid","27710805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38703"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Protein levels in Keap1-Nrf2 system in human failing heart"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","312"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","317"],["dc.bibliographiccitation.volume","218"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Hatanaka, Michiyoshi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:09:59Z"],["dc.date.available","2018-11-07T10:09:59Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Erythropoietin administration, which is clinically used in cancer patients with cancer-induced anemia, has also potentially beneficial effects on nonhematopoietic organs. We assessed the effects of erythropoietin on cancer cachexia progression and cardiac wasting compared with placebo using the Yoshida hepatoma model. Methods: Wistar rats were divided in a sham group (n = 10) and a tumor-bearing group (n = 60). The tumor-bearing group was further randomized to placebo (n = 28), 500 Unit/kg/day (n = 16) or 5000 Unit/kg/day of erythropoietin (n = 16). Body composition was measured using nuclear magnetic resonance spectroscopy, cardiac function using echocardiography, physical activity using infrared monitoring system. Results: Tumor-bearing rats with high dose erythropoietin led to a significant improvement on survival compared with placebo (hazard ratio: 0.43, 95% CI: 0.20-0.92, p = 0.030), though low dose erythropoietin did not reach significance (hazard ratio: 0.46, 95% CI: 0.22-1.02, p = 0.056). Loss of body weight, wasting of lean mass, fat mass, and reduced physical activity were ameliorated in rats treated with both low and high doses of erythropoietin (p < 0.05, all). Moreover, reduced left ventricularmass and left ventricular systolic function were also ameliorated in rats treated with low and high doses of erythropoietin (p < 0.05, respectively). Conclusions: Overall, the present data support that cardiac wasting induced by cancer cachexia plays an important rolewhich leads to impaired survival, provided that the erythropoietin could be an effective therapeutic approach for cancer cachexia progression and cardiac wasting. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.05.008"],["dc.identifier.isi","000377856300052"],["dc.identifier.pmid","27240157"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39764"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]